Companies › Forward Pharmaceuticals
1 active drug program in 3 registered trials: 3 Phase 1; Oncology, Other; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FWD1802 | – | Phase 1 | Healthy; Metastatic Breast Cancer | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07476963 | FWD1802 | Phase 1 | Healthy | Other | Jul 2026 |
| NCT06064812 | FWD1802 | Phase 1 | Metastatic Breast Cancer | Oncology | Mar 2028 |
| NCT07002177 | FWD1802 | Phase 1 | Metastatic Breast Cancer | Oncology | May 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.